References
- 1. Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults: Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31:431-455.
- 2. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38.
- 3. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–72
- 4. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13:450–5.
- 5. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38(4):350.
- 6. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility Agents for the Treatment of Clostridium difficile diarrhea and colitis. Oxford Journals Medicine & Health Clinical Infectious Diseases. 2009; 48(5):598-605.
- 7. Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endoc. 2010;2(8):293-7.
- 8. Grigorescu BL, Fodor RS, Cioc AD, et al. Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients. The Journal of Critical Care Medicine. 2016;2(1):38-43.
- 9. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206-16.
- 10. Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc. 2010;2(8):293–297.
- 11. Stallmach A. Clostridium difficile infection: What is currently available for treatment? Internist (Berl). 2016;57(12):1182-1190.
- 10. Abou Chakra CN, McGeer A, Labbé AC, et al. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. Clin Infect Dis. 2015;61(12):1781-8.
- 11. Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466-71.
- 12. Khanafer N, Barbut F, Eckert C, et al. Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe.2016;37:43-8.
- 13. Mulki R, Baumann AJ, Alnabelsi T, et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2016 Oct 28. doi: 10.1111/apt.13832. [Epub ahead of print]
- 14. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61(3):693-703.
- 15. Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C.Gut Pathog. 2016;8(1):42.
- 16. Naimushin A, Eliasaf S, Livneh A. Clostridium difficile-associated diarrhea: causes and relationship to reactive arthritis. Harefuah. 2011;150(1):64-6.
- 17. Yu JH, Kim NY, Lee HM, et al. A case of pseudomembranous colitis in a juvenile rheumatoid arthritis patient taking methotrexate. Korean J Gastroenterol. 2010;56(6):387-90.
- 18. Vaahtovuo J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008;35(8):1500-5.
- 19. Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147-54.
- 20. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill. 2009;14(45): pii: 19403.
- 21. Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61(2):233-41.
- 22. Dubberke ER, Sadhu J, Gatti R, et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007;28:208–11.
- 23. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical Risk Factors for Severe Clostridium difficile–associated Disease. Emerg Infect Dis. 2009;15(3):415–22.
- 24. Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis. 2016;16:316.
- 25. Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. Infect Dis Ther. 2014;3(2):321–331.
- 26. Gergely Szabo B, Kadar B, Szidonia Lenart K, et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect. 2016. doi: 10.1016/j.cmi.2016.08.017. [Epub ahead of print]
- 27. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011;45(7-8):1005-10.